Related Experiment Video
Updated: Jul 31, 2025

07:21
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
2.1K
Gilteritinib-induced severe immune-related enteritis: a possible case report
Pan Luo1,2, Huiying Qiu3, Yushan Yang1,4
1Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai.
Anti-Cancer Drugs
|May 4, 2023
Summary
This case report details a severe immune-related enteritis possibly caused by gilteritinib in a patient with FLT3-mutated acute myeloid leukemia. Early detection of this adverse drug reaction is crucial for patient management.
Area of Science:
- Oncology
- Pharmacology
- Gastroenterology
Background:
- Gilteritinib is approved in China for FLT3-mutated acute myeloid leukemia (AML).
- Post-marketing surveillance for adverse drug reactions (ADRs) of gilteritinib is essential.
- Immune-related adverse events are a known concern with targeted cancer therapies.

